India Immune-Oncology Drugs: Immunotherapies for Lung Cancer, Market Growth to register a CAGR of 13.1% to reach US$ 461.8 Million by 2027

India Immune-Oncology Drugs Market Analysis

Overview

Biological medicinal products include immuno-oncology products. Lung cancer, breast cancer, bowel cancer, and cervical cancer are among the cancers for which immuno-oncology medications are often used in medicinal applications. The major players in the India immuno-oncology drugs market are concentrating on emerging technology and product growth. Numerous biopharmaceutical companies and academic institutions have been designing biologics for cancer therapy on their own. Researchers at IIT Bombay's Tata Centre for Technology and Design are working on creating an indigenous chimeric antigen receptor T-cell therapy that is affordable to Indian cancer patients.

The India immuno-oncology drugs market was estimated at US$ 172.8 million in 2018 and is projected to develop at a CAGR of 13.1 percent from 2018 to 2026.

Get Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2631

Drivers

The India immune-oncology drugs market is projected to grow due to rising cancer cases and the introduction of novel immuno-oncology therapies.

Over the forecast period, rising cancer incidences are projected to fuel growth of the India immuno-oncology drugs market. Breast cancer incidence was 25.8 per 100,000 women in 2018 and is forecast to cross 35 per 100,000 women in 2026, as per the Indian Council of Medical Research (ICMR) - NICPR (National Institute of Cancer Prevention and Research).

Due to the launch of innovative experimental treatments for cancer therapy with better clinical results, which means additional success rates against cancer, the immune-oncology medicines market is projected to produce a high revenue. Innovative immune therapies will improve the immune system's ability to recognize and kill cancer cells, which is typically suppressed as cancer progresses. These immuno-oncology-based treatments may be customized to strike or block specific targets. Iplimumab is a human monoclonal antibody that inhibits the cytotoxic T-lymphocyte-associated antigen-4.

Tailored Information as per niche requirement:

LIMITED TIME OFFER - Hurry Up!

Exclusive offer!!! Purchase the report at a discounted rate!!!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2631

Cancer medicines such as Sipuleucel-T, Gardasil, and Cervarix have also been developed. These vaccines may be used as either prevention or corrective vaccines. Adoptive cell transplant therapy, also known as CAR-T cell therapy, is a new immuno-oncology treatment that includes Kymriah and Yescarta.

Moreover, for cell lung cancer, organizations focused on various immune regulatory receptors such as simulated death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1) are being used, such as Nivolumab, Atezolimumab, and Pembrolizumab. Covalently monoclonal antibodies, which are paired with other factors such as radiolabeled antibodies and chemo branded antibodies, have been formed from monoclonal antibodies.

Restraints

Inadequate supply of inexpensive and fair cancer treatment drugs in India is a key restraining factor for the India immune-oncology drugs market, which stymies the India immune-oncology drugs market. As per data published in the Lancet Journal in 2014, India's public spending on cancer falls below US$ 10 per person (compared to over US$ 100 per person in high-income or developing countries), and total public spending on healthcare remains just marginally higher than 1% of GDP. Out-of-pocket fees, which contribute for over three-quarters of cancer expenses in India, are one of the biggest risks to patients and their families, according to the same article. Furthermore, since cancer treatments are more expensive, and there are fewer better alternatives available, main players are unable to reduce the cost of cancer drugs.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/india-immune-oncology-drugs-market-to-surpass-us-4618-million-by-2026-1405

Competitive Landscape

Major companies contributing in the India immune-incology drugs market are Dr. Reddy's Laboratories Ltd., Merck & Co., Inc., AstraZeneca plc, Intas Pharmaceuticals Ltd., Amgen, Inc., Biocon Limited, Hetero Drugs Limited., F. Hoffmann-La Roche AG, Reliance Life Sciences, Mylan N.V., BIOCAD-Biotechnology Company, and Bristol - Myers Squibb.

Have a Look at Related Research Insights:

Vitiligo Drug Market To Surpass US$ 348.3 Million By 2027

India Mucormycosis Treatment (Black Fungus Drugs) Market To Surpass US$ 11.7 Million By 2028

Immune Health Supplement Market To Surpass US$ 24,951.0 Million By 2027

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837